A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Part of paid clinical trials in Gilbert, Arizona.
- Sponsor
- Janssen Research & Development, LLC
- Study ID
- NCT06425991
- Phase
- PHASE1
- Status
- Active Not Recruiting
Conditions
- Relapsed or Refractory Multiple Myeloma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Teclistamab — DRUGTeclistamab will be administered subcutaneously.
Study Details
The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between teclistamab made from the current commercial manufacturing process (pre-change) and the new manufacturing process (post-change).
Key Dates
- Start date
- Jun 7, 2024
- Status verified
- Apr 2026
- Primary completion
- Feb 28, 2027
- Completion
- Mar 3, 2027
Study Design
- Enrollment
- 108 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm A: Pre-change TeclistamabParticipants will receive teclistamab monotherapy (made from the pre-change manufacturing process) for all step-up and treatment doses until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent to treatment, or end of the study, whichever occurs first.
- Experimental: Arm B: Post-change TeclistamabParticipants will receive teclistamab monotherapy (made from the post-change manufacturing process) for all step-up and treatment doses until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent to treatment, or end of the study, whichever occurs first.
Primary Outcome Measure
Maximum Observed Serum Concentration (Cmax) of First Treatment Dose of Teclistamab [ Time Frame: Cycle 1 (28 days cycle): Predose to Day 7 postdose ]
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | - |
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | - |
| Cleveland Clinic Florida | Weston | Florida | 33331 | - |
| Augusta University- Georgia Cancer Center | Augusta | Georgia | 30912 | - |
| St Francis Hospital & Health Centers Indiana Blood and Marrow Transplantation Franciscan Health | Indianapolis | Indiana | 46237 | - |
| Cleveland Clinic | Cleveland | Ohio | 44195 | - |
| Baylor University Medical Center | Dallas | Texas | 75246 | - |
Find similar trials in Gilbert, AZ
By research site
Banner MD Anderson Cancer Center· Gilbert, AZColorado Blood Cancer Institute· Denver, COCleveland Clinic Florida· Weston, FLAugusta University- Georgia Cancer Center· Augusta, GASt Francis Hospital & Health Centers Indiana Blood and Marrow Transplantation Franciscan Health· Indianapolis, INCleveland Clinic· Cleveland, OH
Related Studies
- A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)PHASE3 · Recruiting · Celgene · Los Alamitos, California
- A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) AmyloidosisPHASE1 · Recruiting · Janssen Research & Development, LLC · Duarte, California
- Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple MyelomaPHASE1 · Recruiting · Jiangsu Simcere Pharmaceutical Co., Ltd. · Phoenix, Arizona
- A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple MyelomaPHASE1/PHASE2 · Recruiting · ModernaTX, Inc. · Birmingham, Alabama